Jefferies raised the firm’s price target on Exact Sciences to $110 from $100 and keeps a Buy rating on the shares after a Q2 beat and 2023 guidance was raised “again” by more than the beat. Given elevated buyside expectations into the print, the stock may consolidate recent gains, but the latest update “adds further credibility to the profitability/FCF inflection thesis,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS:
- AMD upgraded, Electronic Arts downgraded: Wall Street’s top analyst calls
- Exact Sciences price target raised to $120 from $115 at Canaccord
- Exact Sciences price target raised to $110 from $105 at BofA
- Exact Sciences price target raised to $90 from $75 at Credit Suisse
- Exact Sciences price target raised to $121 from $99 at Baird